Detection of Tumor-Related Biomarkers in Hepatocellular Carcinoma Patients by Sequencing Circulating Cell-Free DNA

Hao Wang1 , Huabang Zhou1 , Xiaoyan Li1 , Peng Wang1 , Guofang Liu1 , Wendi Liu1 , Liping Lei1 , Nan He2 and Heping Hu1 *

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, ChinaShanghai AccuraGen Biotechnology Co Ltd, China

^*Correspondance to: Heping Hu 

 PDF  Full Text Research Article | Open Access

Abstract:

In this study, we sequenced paired Cell-Free DNA (cfDNA) and tumor tissue DNA samples from 16 Hepatitis B Virus (HBV)-infected Hepatocellular Carcinoma (HCC) patients to detect tumor-related biomarkers in cfDNA samples. We analyzed a panel of 41 HCC-related target genes and detected 35 mutations among 13 genes in 10 HCC samples as well as 14 mutations among 7 genes in 6 cfDNA samples. The top 6 mutant genes were TP53 (22.86%), TERT (20%), ALB (14.29%), AXIN1 (11.43%), FLT1 (5.71%) and ARID1A (5.71%). The mutation relevance ratios of matched HCC tissues and cfDNA samples were not associated with tumor size or serum α-Fetoprotein (AFP) levels. The TERT upstream gene variants, -124C>T (chr5:g.1295228G>A) is the only mutation shared by more than one case. Tumors with ALB mutations were associated with more gene mutations than tumors without ALB mutations (p=0.021407). Our study demonstrates the feasibility of cfDNAbased sequencing for detecting circulating tumor DNA biomarkers in HCC patients

Keywords:

HCC; cfDNA; Matched; Targeted Sequencing

Cite the Article:

Wang H, Zhou H, Li X, Wang P, Liu G, Liu W, et al. Detection of TumorRelated Biomarkers in Hepatocellular Carcinoma Patients by Sequencing Circulating Cell-Free DNA. Clin Oncol. 2019; 4: 1645 .